Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
New technique could help fine-tune the production of useful proteins

New technique could help fine-tune the production of useful proteins

Researchers work on DNA-delivered antibodies to stop COVID-19

Researchers work on DNA-delivered antibodies to stop COVID-19

COVID-19 vaccination stimulates antibodies aiming parts of virus spike protein among corona variants, researchers discover

COVID-19 vaccination stimulates antibodies aiming parts of virus spike protein among corona variants, researchers discover

Spirea raises £2.4M ($3M) to develop antibody drug conjugates   in cancer

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Human nose organoids reveal the first events of SARS-CoV-2 and RSV infection

Human nose organoids reveal the first events of SARS-CoV-2 and RSV infection

Single-cell sequencing technique helps to examine early SARS-CoV-2 infection

Single-cell sequencing technique helps to examine early SARS-CoV-2 infection

A folic acid-like drug changes a DNA process within brain tumors

A folic acid-like drug changes a DNA process within brain tumors

Duke engineers develop a rapid test to identify antibody effectiveness against COVID-19 variants

Duke engineers develop a rapid test to identify antibody effectiveness against COVID-19 variants

Study finds amphipathic peptide that safely opens endosomal membrane

Study finds amphipathic peptide that safely opens endosomal membrane

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Experts develop antibodies that effectively remove senescent cells

Experts develop antibodies that effectively remove senescent cells

Study identifies highly potent monoclonal antibody against all SARS-CoV-2 variants

Study identifies highly potent monoclonal antibody against all SARS-CoV-2 variants

Novel Assay Platform for 3D Microfluidic Cancer Research

Novel Assay Platform for 3D Microfluidic Cancer Research

New map provides a reference to predict which antibodies are effective against SARS-CoV-2

New map provides a reference to predict which antibodies are effective against SARS-CoV-2

Researchers provide novel treatment target for common skin condition

Researchers provide novel treatment target for common skin condition

New drug delivery strategy could make it easier for patients to take their medications

New drug delivery strategy could make it easier for patients to take their medications

Newly designed higher affinity monoclonal antibody for cancer treatment

Newly designed higher affinity monoclonal antibody for cancer treatment

Key discovery could prevent treatment failure in people with severe hemophilia A

Key discovery could prevent treatment failure in people with severe hemophilia A

Immunity of COVID-19 patients may rely on antibodies from previous coronavirus infections

Immunity of COVID-19 patients may rely on antibodies from previous coronavirus infections

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.